BFM
ELDN icon

Boothbay Fund Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Boothbay Fund Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-151,569
Closed -$229K – 2175
2025
Q4 		$229K Buy
+151,569
New +$360K ﹤0.01% 1600
2025
Q3 		– Sell
-293,565
Closed -$796K – 1937
2025
Q2 		$796K Sell
293,565
-18,593
-6% -$55.8K 0.02% 764
2025
Q1 		$1.06M Sell
312,158
-29,765
-9% -$122K 0.03% 609
2024
Q4 		$1.41M Buy
+341,923
New +$1.35M 0.03% 541
2023
Q3 		– Sell
-22,050
Closed -$30.2K – 1819
2023
Q2 		$30.2K Hold
22,050
– – ﹤0.01% 1702
2023
Q1 		$52K Hold
22,050
– – ﹤0.01% 2015
2022
Q4 		$50.3K Hold
22,050
– – ﹤0.01% 1876
2022
Q3 		$61K Sell
22,050
-12,580
-36% -$40.1K ﹤0.01% 2097
2022
Q2 		$85K Hold
34,630
– – ﹤0.01% 2008
2022
Q1 		$136K Hold
34,630
– – ﹤0.01% 2024
2021
Q4 		$153K Hold
34,630
– – ﹤0.01% 1585
2021
Q3 		$214K Sell
34,630
-5,422
-14% -$37.9K 0.01% 1530
2021
Q2 		$317K Buy
40,052
+11,360
+40% +$107K 0.01% 1241
2021
Q1 		$307K Buy
+28,692
New +$433K 0.01% 1178

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Boothbay Fund Management's ELDN Position: Q1 2026 in Review

Boothbay Fund Management sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 151,569 shares — an estimated $229K sold.

Boothbay Fund Management first reported a position in ELDN in Q1 2021 and held it in 14 quarters. The position peaked at $1.41M in Q4 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Boothbay Fund Management reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 151,569 Eledon Pharmaceuticals shares in Q1 2026, an estimated $229K.
  • Boothbay Fund Management first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • Boothbay Fund Management's Eledon Pharmaceuticals position peaked at $1.41M in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.